#Canada #Montreal #Thryv Therapeutics #SGK1 inhibitors #Amy Rudolph

Amy Rudolph, PhD, Joins Thryv Therapeutics' Board of Directors

In a significant move for Thryv Therapeutics Inc., a clinical-stage biotechnology company, Dr. Amy Rudolph has been appointed to its Board of Directors. This announcement indicates the company's focus on progressing its innovative therapies for heart failure and other serious cardiovascular conditions. Dr. Rudolph brings over 25 years of robust experience in the global pharmaceutical landscape, having held key leadership roles throughout her career.

Currently, Dr. Rudolph serves as the Head of Global Medical Affairs and Cross-TA Medical Affairs at Boehringer Ingelheim. In this position, she spearheads a comprehensive transformation initiative aimed at building a leading Medical Affairs organization. This organization focuses on enhancing external engagement, integrating digital and AI solutions, generating evidence, and applying advanced analytics. Her strong leadership in these areas is expected to be a considerable asset as Thryv Therapeutics continues to develop its SGK1 inhibitor portfolio.

Paul Truex, Chairman and CEO of Thryv Therapeutics, expressed excitement about Dr. Rudolph’s joining the board: "We are thrilled to welcome Amy Rudolph to our Board of Directors. Her extensive experience in medical affairs and drug development will be invaluable as we seek to advance our SGK1 inhibitor pipeline towards late-stage clinical studies."

Dr. Rudolph's extensive career includes significant milestones at Novartis Pharmaceutical Corporation, where she held the position of Head of HCS Partnerships in Global Drug Development and was also responsible for Evidence and Launch Excellence in Global Medical Affairs. She has also served in key roles at Pfizer Inc., where her contributions were crucial in the development of numerous cardiovascular therapies. Her track record includes involvement in the launches of high-profile medications such as Lipitor, Eliquis, and Entresto.

In her new role at Thryv, Dr. Rudolph aims to leverage her experience to tackle the pressing challenges faced in treating cardiovascular conditions. "I am honored to join Thryv Therapeutics' Board of Directors," she said. "The company’s scientific approach and patient-centered mission deeply resonate with me, and I look forward to supporting its progress in addressing serious cardiovascular conditions."

Dr. Rudolph's appointment comes as Scott Weiner transitions to an observer role on the board after serving since 2021. However, Weiner will continue his involvement with Thryv Therapeutics, maintaining a closely-knit advisory relationship and remaining on the board of the company’s subsidiary, Thryv Therapeutics USA, Inc.

Overview of Thryv's SGK1 Inhibitor Platform

Thryv Therapeutics is dedicated to advancing its SGK1 inhibitor platform, which focuses on potent and selective SGK1 inhibitors. These inhibitors address vital mechanisms underlying electrical and structural remodeling in the heart, presenting promising new avenues for treatment. The company’s lead candidate, THRV-1268, is notably a highly selective SGK1 inhibitor. It holds the potential to revolutionize treatment for serious conditions, including Long QT Syndrome, heart failure, and atrial fibrillation.

Based in Montreal, Quebec, Thryv Therapeutics is pioneering a precision medicine approach to treat genetic channelopathies and related cardiometabolic diseases. The ongoing commitment to delivering precise and effective therapies establishes Thryv as a notable player in the biotechnology field. For further details, you can visit their official website at www.thryvtrx.com.